---
title: 'Performance of MYC, BCL2, and BCL6 break-apart FISH in small biopsies with
  large B-cell lymphoma: a retrospective Cytopathology Hematopathology Interinstitutional
  Consortium study'
date: '2024-06-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38903717/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240622182853&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'INTRODUCTION: Fluorescence in situ hybridization (FISH) is an essential
  ancillary study used to identify clinically aggressive subsets of large B-cell lymphomas
  that have MYC, BCL2, or BCL6 rearrangements. Small-volume biopsies such as fine
  needle aspiration biopsy (FNAB) and core needle biopsy (CNB) are increasingly used
  to diagnose lymphoma and obtain material for ancillary studies such as FISH. However,
  the performance of FISH in small biopsies has not been thoroughly evaluated or compared
  ...'
disable_comments: true
---
INTRODUCTION: Fluorescence in situ hybridization (FISH) is an essential ancillary study used to identify clinically aggressive subsets of large B-cell lymphomas that have MYC, BCL2, or BCL6 rearrangements. Small-volume biopsies such as fine needle aspiration biopsy (FNAB) and core needle biopsy (CNB) are increasingly used to diagnose lymphoma and obtain material for ancillary studies such as FISH. However, the performance of FISH in small biopsies has not been thoroughly evaluated or compared ...